272 related articles for article (PubMed ID: 24425785)
1. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.
Li H; Wawrose JS; Gooding WE; Garraway LA; Lui VW; Peyser ND; Grandis JR
Mol Cancer Res; 2014 Apr; 12(4):571-82. PubMed ID: 24425785
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
3. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
[TBL] [Abstract][Full Text] [Related]
4. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
[TBL] [Abstract][Full Text] [Related]
5. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Lui VW; Hedberg ML; Li H; Vangara BS; Pendleton K; Zeng Y; Lu Y; Zhang Q; Du Y; Gilbert BR; Freilino M; Sauerwein S; Peyser ND; Xiao D; Diergaarde B; Wang L; Chiosea S; Seethala R; Johnson JT; Kim S; Duvvuri U; Ferris RL; Romkes M; Nukui T; Kwok-Shing Ng P; Garraway LA; Hammerman PS; Mills GB; Grandis JR
Cancer Discov; 2013 Jul; 3(7):761-9. PubMed ID: 23619167
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
8. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
10. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
11. Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy.
Lepikhova T; Karhemo PR; Louhimo R; Yadav B; Murumägi A; Kulesskiy E; Kivento M; Sihto H; Grénman R; Syrjänen SM; Kallioniemi O; Aittokallio T; Wennerberg K; Joensuu H; Monni O
Mol Cancer Ther; 2018 Sep; 17(9):2060-2071. PubMed ID: 29970484
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Al-Amri AM; Vatte C; Cyrus C; Chathoth S; Hashim TM; Mohamed YS; Al Ali R; Alsaid A; Al Ali A
Cancer Biomark; 2016; 16(3):377-83. PubMed ID: 26889984
[TBL] [Abstract][Full Text] [Related]
13. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
Göke F; Franzen A; Hinz TK; Marek LA; Yoon P; Sharma R; Bode M; von Maessenhausen A; Lankat-Buttgereit B; Göke A; Golletz C; Kirsten R; Boehm D; Vogel W; Kleczko EK; Eagles JR; Hirsch FR; Van Bremen T; Bootz F; Schroeck A; Kim J; Tan AC; Jimeno A; Heasley LE; Perner S
Clin Cancer Res; 2015 Oct; 21(19):4356-64. PubMed ID: 26015511
[TBL] [Abstract][Full Text] [Related]
14. The Proteomic Landscape of Growth Factor Signaling Networks Associated with
Chen Z; Zhang C; Chen J; Wang D; Tu J; Van Waes C; Saba NF; Chen ZG; Chen Z
Cancer Res; 2021 Sep; 81(17):4402-4416. PubMed ID: 34167951
[TBL] [Abstract][Full Text] [Related]
15. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
[TBL] [Abstract][Full Text] [Related]
16. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
17. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
18. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.
Nisa L; Barras D; Medová M; Aebersold DM; Medo M; Poliaková M; Koch J; Bojaxhiu B; Eliçin O; Dettmer MS; Angelino P; Giger R; Borner U; Caversaccio MD; Carey TE; Ho L; McKee TA; Delorenzi M; Zimmer Y
Mol Cancer Res; 2018 Dec; 16(12):1912-1926. PubMed ID: 30108165
[TBL] [Abstract][Full Text] [Related]
20. Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.
Sepiashvili L; Hui A; Ignatchenko V; Shi W; Su S; Xu W; Huang SH; O'Sullivan B; Waldron J; Irish JC; Perez-Ordonez B; Liu FF; Kislinger T
Mol Cell Proteomics; 2012 Nov; 11(11):1404-15. PubMed ID: 22918226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
